Methotrexate Treatment for Ectopic Pregnancy

Phase 3

Completed

• Conditions: Ectopic Pregnancy

• Registration Number: NCT01855568
• Lead Sponsor: CHA University

Brief Summary

Ectopic pregnancy is an important cause of maternal morbidity and occasionally mortality. Deaths associated with ectopic pregnancy have declined, though approximately 75% of deaths in the first trimester and 9-13% of all pregnancy-related deaths are associated ectopic pregnancy. The main stays of management for ectopic pregnancy were surgery and medical treatment. Medical management with systemic methotrexate administration avoids the inherent morbidity of anesthesia and surgery is cost-effective, and also offers success rates comparable to surgical management, with no loss in future potential fertility.

However, although medical management using methotrexate is used commonly, there is no solid consensus regarding dose protocol. Currently, there are three methotrexate protocols for the treatment of an ectopic pregnancy, "multi-dose", "single-dose", or "two-dose". Among them, the multi-dose protocol includes the administration of 4 methotrexate doses alternating with leucovorin (rescue regimen). As a result of the multiple dosing of methotrexate, side effects are more common. In contrast, the advantages of the single-dose protocol include elimination of a rescue regimen, lower incidence of adverse effects, and better compliance. However, the single-dose protocol was found to be associated with a considerably lower success rate as compared with the multi-dose protocol (88% versus 93%) in a recent meta-analysis. The two-dose protocol, which it balances efficacy and safety/convenience, was described as a cross between the multi-dose and single-dose protocols.

However, there were a few studies comparing between single-dose and two-dose protocol. The purpose of this prospective randomized trial was to compared the success rates of single-dose and two-dose methotrexate protocol for the treatment of tubal ectopic pregnancy.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-05
• Study First Submitted: 2013-05-10
• Study First Submitted QC: 2013-05-14
• Study First Posted: 2013-05-16
• Primary Completion: 2015-04
• Study Completion: 2015-04
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-21
• Last Update Posted: 2016-01-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 92

Inclusion Criteria

• tubal pregnancy
• tubal pregnancy except interstitial pregnancy
• a pretreatment β-hCG level <15000 mIU/mL
• a gestational sac with a largest diameter <4 cm
• hemodynamically stable status
• agreement to methotrexate treatment and follow up

Exclusion Criteria

• heterotrophic pregnancy
• a presence of embryonic cardiac motion
• clinically or sonographically suspected tubal rupture
• laboratory tests showing possible deleterious effects of methotrexate treatment on organ functions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
treatment success	Up to 8 weeks (normal recovery time after treatment)	Participants in both groups were considered a treatment success if β-hCG levels resolved to \<5 mIU/mL without surgical intervention. The cases of participants who underwent surgical intervention were considered to have had treatment failure.

Trial Locations

Locations (1)

CHA Gangnam Medical Center; 🇰🇷 Seoul, Korea, Republic of